ArticleBMC infectious diseases2026
Bridging the gap between guidelines and practice: real-world evaluation of Candida management and outcomes in a Turkish tertiary care center.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCandida species are important causes of morbidity and mortality, with increasing antifungal resistance representing a major clinical challenge. Guideline adherence plays a critical role in optimizing outcomes.
methodsThis retrospective study included adult patients hospitalized at a tertiary care center between 2022 and 2023 with Candida species isolated from blood, urine, tracheal aspirate, catheter tip, tissue, or oral swab samples. Demographic, clinical, and laboratory data were obtained from electronic records. Invasive candidiasis and colonization were defined according to the IDSA 2016 and ESCMID 2012 guidelines. The EQUAL Candida score was used to assess compliance in candidemia.
resultsA total of 316 patients were included; the mean age was 64.4 ± 18.0 years, and 54.1% were female. C. albicans accounted for 83.2% of isolates identified at the time of growth and 35.0% of those identified retrospectively. Candidozyma auris was detected exclusively among retrospectively identified isolates and was more frequent in patients with prior antifungal exposure. The most common site of isolation was urine (47.1%), followed by respiratory tract (23.2%) and bloodstream (12.3%). Compliance with the IDSA and ESCMID guidelines for candiduria was 84.4% and 85.1%, respectively; however, 31.3% of patients who received antifungal therapy were deemed to have been treated unnecessarily. In candidemia, the mean EQUAL Candida score was 13.5 ± 4.8, and 30-day mortality was 46.8%.
conclusionAdherence to international guidelines in this real-world cohort was high, yet mortality remained substantial. Non-albicans Candida and Candidozyma auris were more frequent in patients with prior antifungal exposure, highlighting the need for improved antifungal stewardship in routine clinical practice. CLINICAL TRIAL NUMBER: Not applicable. (No individual or identifiable patient data are included in this manuscript.)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.